Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: Immediate and midterm results of an international registry

被引:145
|
作者
Holzer, Ralf
de Giovanni, Jo
Walsh, Kevin P.
Tometzki, Andrew
Goh, T. H.
Hakim, Fakhri
Zabal, Carlos
de Lezo, Jose Suarez
Cao, Qi-Ling
Hijazi, Ziyad M.
机构
[1] Univ Chicago, Corner Childrens Hosp, Pritzker Sch Med, Dept Pediat,Sect Cardiol, Chicago, IL 60637 USA
[2] Childrens Hosp, Birmingham, W Midlands, England
[3] Our Ladys Hosp Sick Children, Dublin, Ireland
[4] Childrens Hosp, Bristol, Avon, England
[5] Royal Childrens Hosp, Melbourne, Vic, Australia
[6] Queen Alia Heart Inst, Amman, Jordan
[7] Inst Nacl Cardiol Ignacio Chavez, Mexico City, DF, Mexico
[8] Hosp Reina Sofia, Cordoba, Spain
关键词
perimembranous ventricular septal defect; catheterization; interventional;
D O I
10.1002/ccd.20659
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To report the immediate and midterm results of transcatheter closure of perimembranous ventricular septal defect (PmVSD) using the Amplatzer membranous VSD occluder (AMVSD). Methods: Between April 2002 and August 2004, 100 patients underwent an attempt of percutaneous device closure of PmVSD using the AMVSD in 24 international centers. The median age was 9.0 years (0.7-58 years) and the median weight was 27.5 kg (7-121 kg). Results: A device was successfully deployed in 93/100 (93%) patients. Reasons for procedural failure were an increased gradient across the left ventricle outflow tract in one patient, aortic regurgitation in 2 patients, and inability to securely position the device in 4 patients. The median VSD size by TEE was 7.0 mm (1.5-13 mm), median device size 10 mm (4-16 mm) and median fluoroscopy time 22.1 min (8.9-96.0 min). Weight below 10 kg (P = 0.0392), inlet extension of the VSD (P = 0.0139) and aortic cusp prolapse into the VSD (P = 0.0084) were significantly associated with a lower procedural success. Patients have been followed up for a median of 182 days (1-763 days). There were no procedure-related deaths. Complications were encountered in 29/100 (29%) patients, including rhythm or conduction anomalies in 13 patients (two with complete heart block requiring permanent pacemaker implantation), new or increased aortic (9 patients) or tricuspid (9 patients) regurgitation, most of which were classified as trivial or mild. Patients with a weight below 10 kg had a significantly higher incidence of adverse events than patients with a weight above 10 kg (58.3% versus 25.0%, P = 0.0285). Immediately after device release complete closure of the defect was present in 54/93 (58.1%) patients, increasing to 46/55 (83.6%) patients at 6-months follow-up (P = 0.0012). Left ventricle end-diastolic diameter decreased from a median of 44 mm prior to device closure to a median of 39 mm at 6-months postprocedure (P = 0.0015). Conclusion: Closure of PmVSDs using the AMVSD occluder is safe and effective. However, longer follow-up period is warranted prior to the wide spread use of this device. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:620 / 628
页数:9
相关论文
共 50 条
  • [1] Transcatheter closure of perimembranous ventricular septal defects using the Amplatzer membranous VSD occluder: Immediate results
    Holzer, RJ
    Hijazi, ZM
    Wilkinson, J
    Sievert, H
    DeGiovanni, J
    Hakim, F
    Walsh, K
    Hroob, A
    Bonhoeffer, P
    CIRCULATION, 2003, 108 (17) : 705 - 705
  • [2] Transcatheter closure of perimembranous ventricular septal defect with the Amplatzer® Membranous VSD Occluder 2
    Tzikas, Apostolos
    Aguirre, Daniel
    Velasco-Sanchez, Daniel
    Freixa, Xavier
    Alburquenque, Marcela
    Khairy, Paul
    Bass, John
    Ramirez, Juan
    Ibrahim, Reda
    Miro, Joaquim
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) : B225 - B225
  • [3] Transcatheter closure of perimembranous ventricular septal defects: Initial human experience with the Amplatzer® membranous VSD occluder 2
    Velasco-Sanchez, Daniel
    Tzikas, Apostolos
    Ibrahim, Reda
    Miro, Joaquim
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2013, 82 (03) : 474 - 479
  • [4] Transcatheter closure of perimembranous ventricular septal defects using the new amplatzer membranous VSD occluder - Results of the US phase I trial
    Fu, YC
    Bass, J
    Amin, Z
    Radtke, W
    Cheatham, JP
    Hellenbrand, WE
    Balzer, D
    Cao, QL
    Hijazi, ZM
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (02) : 319 - 325
  • [5] Transcatheter closure of perimembranous ventricular septal defect using the cocoon membranous VSD occluder
    Singhi, Anil Kumar
    Mohapatra, Soumya Kanti
    De, Arnab
    PROGRESS IN PEDIATRIC CARDIOLOGY, 2024, 74
  • [6] Catheter closure of perimembranous/membranous ventricular septal defects using the amplatzer occluder device
    Thanopoulos, BD
    PEDIATRIC CARDIOLOGY, 2005, 26 (04) : 311 - 314
  • [7] Catheter Closure of Perimembranous/Membranous Ventricular Septal Defects Using the Amplatzer Occluder Device
    B. D. Thanopoulos
    Pediatric Cardiology, 2005, 26 : 311 - 314
  • [8] Catheter closure of perimembranous ventricular septal defects using the new amplatzer membranous VSD occluder: Initial clinical experience
    Hijazi, ZM
    Hakim, F
    Abu Haweleh, A
    Madani, A
    Tarawna, W
    Hiari, A
    Cao, OL
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2002, 56 (04) : 508 - 515
  • [9] Catheter closure of perimembranous ventricular septal defects using the new amplatzer membranous VSD occluder: Initial clinical experience
    Hijazi, ZM
    Hakim, F
    Madani, A
    Abu Haweleh, A
    Tarawneh, W
    Hiari, A
    Cao, QL
    CIRCULATION, 2002, 106 (19) : 486 - 486
  • [10] Transcatheter closure of perimembranous ventricular septal defects in infants and children using the amplatzer perimembranous ventricular septal defect occluder
    Thanopoulos, Basil Vasilios D.
    Rigby, Michael L.
    Karanasios, Evangelos
    Stefanadis, Christodoulos
    Blom, Nico
    Ottenkamp, Jaap
    Zarayelyan, Armine
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (07): : 984 - 989